Certain PARP inhibitors (PARPi) are FDA-approved to treat breast, prostate, and gynecologic cancers including ovarian cancer (21–23), and there are numerous clinical trials underway to extend their use to other malignancies (Table 1). The gene discussed is PARP1; the disease is ovarian cancer.